Pharma Stock Up 4.5%; Q1 Profit Jumps 31% as Company Targets Rs 1,000 Crore Revenue

On Thursday, Indian equity benchmark indices traded lower, with the benchmark Nifty 50 index falling 40.10 points, or around 0.16 per cent, to 24,395.85. Amid the market movement, Lincoln Pharmaceuticals share price rose 4.50 per cent to Rs 619.50 after the company reported a strong Q1 FY27 performance, with consolidated net profit rising 30.90 per cent YoY.

Net Profit Rises 30.90 per cent YoY

Lincoln Pharmaceuticals reported consolidated net profit of Rs 36.23 crore for the quarter ended June 30, 2026, compared with Rs 27.68 crore in Q1 FY26, registering a 30.90 per cent YoY increase.

Total income increased 19.02 per cent YoY to Rs 201.55 crore from Rs 169.34 crore. EBITDA grew at a faster pace, rising 32.29 per cent to Rs 51.70 crore from Rs 39.08 crore in the corresponding quarter. Profit before Tax increased 34.36 per cent YoY to Rs 47.55 crore, while EPS improved to Rs 18.09 from Rs 13.82.

For FY26, the company reported total income of Rs 704.48 crore, up 9.10 per cent YoY, while net profit increased 6.74 per cent to Rs 87.89 crore. EBITDA stood at Rs 131.14 crore, registering growth of 5.78 per cent.

Targets Rs 1,000 Crore Revenue

Lincoln Pharmaceuticals is targeting revenue of Rs 1,000 crore over the next three years and aims to achieve annual growth of 15-18 per cent. The company expects cardiac, diabetic, dermatology and ENT therapies to remain key growth drivers.

The company has developed more than 600 formulations across 15 therapeutic areas and has over 1,700 registered products, with another 700 products under development. Its portfolio covers anti-infective, respiratory, gynaecology, cardio and CNS, anti-bacterial, anti-diabetic and anti-malaria therapies.

Global Expansion in Focus

Lincoln Pharmaceuticals currently exports to more than 60 countries across Africa, Central and North America, Latin America and Southeast Asia. The company plans to expand its presence to 90 countries over the next two to three years.

The company has recently entered the Canadian market and holds approvals including EU GMP and TGA Australia, supporting its expansion into regulated markets.

Its manufacturing facilities at Khatraj and Mehsana in Gujarat are equipped to manufacture tablets, capsules, injectables, syrups and ointments. The company has also filed more than 25 patent applications and has been granted seven patents.

Debt-Free Balance Sheet and FII Holding

Lincoln Pharmaceuticals continues to maintain a net-debt-free balance sheet. FII holding stood at 4.60 per cent as of June 30, 2026.

The company has also recommended a Dividend of 18 per cent, equivalent to Rs 1.80 per share on a face value of Rs 10, for FY26, subject to shareholder approval at the upcoming Annual General Meeting.

Lincoln Pharmaceuticals Share Price

Lincoln Pharmaceuticals shares were trading at Rs 619.50, up 4.50 per cent on Thursday, outperforming the broader market. The stock remained in focus following the company's Q1 FY27 results, which showed double-digit growth in revenue, EBITDA and net profit.

The company's Rs 1,000 crore revenue target, expansion into international markets, product pipeline and debt-free balance sheet remain key developments to watch going forward.
Also Read - This Low PE, High ROCE Stock Iron & Steel Company Outlines FY26 Growth Strategy; PAT Rises 27.4% to Rs 3,185 Crore

Share your thoughts on this development in the comments below.
Disclaimer: The article is for informational purposes only and not investment advice.